2+ day, 16+ hour ago   (478+ words) The company recently disclosed that its antibody-oligo conjugate drug failed to meet trial endpoints. Earlier this week, Novartis announced that its antibody-oligonucleotide conjugate (AOC) drug delpacibart etedesiran (del-desiran) failed to meet primary endpoints in a Phase III clinical trial. The…...

3+ day, 17+ hour ago   (1031+ words) Three leaders shared how straight talk, low egos, and cost efficiency are turning Scandinavian startups into pharma's trusted collaborators. The Nordic biotech ecosystem could be said to be punching above its weight, and three CEOs at the heart of this…...

1+ week, 7+ hour ago   (494+ words) In a deal that could be worth close to $1.3 billion, HUTCHMED has signed a licensing agreement with GSK for one of its oncology assets. HUTCHMED Limited has granted a subsidiary of GSK, GlaxoSmithKline Intellectual Property (No.4) Limited, worldwide rights to…...

1+ week, 5+ day ago   (609+ words) Research shows pharma companies identify clinical trial risks well but lack the organizational capability to implement effective solutions. Sponsors and CROs are effective at detecting problems with trials, but they are less adept at taking corrective action, according to new…...

2+ week, 5+ day ago   (292+ words) The companies are working to advance neridronate toward potential first US Food and Drug Administration (FDA) approval for complex regional pain syndrome type 1 (CRPS-1). The combined entity will operate as Ambros Therapeutics and is expected to trade on Nasdaq under…...

2+ week, 5+ day ago   (1066+ words) Mary Clark, CEO of Optimum Strategic Communications, discusses how capital, partnering and M&A now concentrate around credible execution and strategic relevance. The biopharma sector is experiencing what Clark describes as a "selective recovery" rather than a broad market reopening....

3+ week, 2+ day ago   (442+ words) Fulcrum Therapeutics and Slate Medicines have agreed to combine in a reverse merger, giving the migraine specialist a fast route to the public markets. Slate's lead candidate, SLTE-1009, is a subcutaneous monoclonal antibody that blocks both PACAP and VIP, two…...

3+ week, 2+ day ago   (322+ words) BioMarin will expand its rare disease portfolio with a potential first-in-class oral therapy for hypophosphatasia called ALE1. "ALE1 is a strong strategic fit for BioMarin, bringing a potential oral alternative to the injectable therapies available today for people living with HPP around…...

3+ week, 5+ day ago   (403+ words) Sponsors and CROs often use study-specific conventions that create duplication risks, hinder subject tracking, and fragment data across portfolios. Industry subject ID practices increase the risk of duplication, make it harder to track study subjects and complicate submissions, according to…...

4+ week, 1+ day ago   (415+ words) The New York-based biotech debuts with quarterly-dosing antibody for kidney disease and precision immunology platform backed entirely by Deerfield Management. Boulevard Bio has stepped out of stealth mode with approximately $65 million in launch financing. The clinical-stage company, backed entirely by…...